Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels.

Trial Profile

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Oct 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 21 Oct 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top